BioSpace News Archive

Business

Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology

Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology.

March 22, 2023
·
9 min read
Genetown

Dewpoint Therapeutics partners with Novo Nordisk to explore the field of biomolecular condensates to treat insulin resistance and diabetes progression

Dewpoint Therapeutics today announced a research and development partnership with Novo Nordisk to identify drug candidates using Dewpoint’s discovery platform related to biomolecular condensates to treat insulin resistance and diabetic complications.

March 22, 2023
·
4 min read
Drug Development

Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders

Biohaven Ltd. (NYSE: BHVN) today announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders.

March 22, 2023
·
8 min read
Business

Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

March 22, 2023
·
20 min read
Business

InflaRx Reports Full Year 2022 Financial and Operating Results

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced financial and operating results for the year ended December 31, 2022.

March 22, 2023
·
19 min read
Pharm Country

ANNOVIS BIO ANNOUNCES TWO PRESENTATIONS AT THE AD/PD™ 2023 INTERNATIONAL CONFERENCE ON ALZHEIMER’S AND PARKINSON’S DISEASES

Annovis Bio, Inc. today announced the Company will be making two presentations at the upcoming AD/PD ™ 2023 International Conference on Alzheimer’s and Parkinson’s Disease, which is taking place from March 28 through April 1, 2023, in Gothenburg, Sweden.

March 22, 2023
·
6 min read
Business

Capstan Therapeutics Appoints Justin Thacker as Chief Financial Officer and Jeffrey Pepe, J.D., Ph.D., as General Counsel

Capstan Therapeutics, Inc. today announced the appointment of Justin Thacker as Chief Financial Officer and Jeffrey Pepe, J.D., Ph.D. as General Counsel.

March 22, 2023
·
2 min read
Genetown

Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Acer Therapeutics Inc. announced that it has entered into a definitive agreement for the purchase and sale of 2,920,306 shares of the Company’s common stock at a purchase price of $0.916 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.

March 22, 2023
·
5 min read
Business

CND Life Sciences Enters into Licensing and Collaboration Agreement to Advance Diagnostic Technology for Neurodegenerative Diseases

CND Life Sciences has entered into a licensing collaboration with Beth Israel Deaconess Medical Center (BIDMC) in Boston to advance CND’s scientific platform and patient-focused mission.

March 22, 2023
·
4 min read
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023

RELIEF THERAPEUTICS Holding SA announces survey results identifying preferred urea cycle disorder treatment attributes from its collaboration partner ACER Therapeutics, Inc.

March 22, 2023
·
8 min read